Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01265199
Recruitment Status : Terminated (Study was terminated before a MTD was determined for administrative reasons)
First Posted : December 23, 2010
Last Update Posted : January 23, 2013
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Ascenta Therapeutics

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : January 2013
  Actual Study Completion Date : January 2013